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Abstract The pace of genomic discoveries in the field of
cancer is revolutionizing our understanding of the biolog-
ical dynamics of cancerous growth and, at the same time,
fueling research for newer and smarter cancer therapies to
reverse the effects of these alterations. These dynamics are
driving a tremendous paradigm shift in cancer diagnostics,
drug development and clinical trial design with the hope of
eliminating the current structure and approach of cancer
care, to one which is driven by the underlying biology of
the tumor and, thus highly personalized. Much of this
paradigm shift has been fueled by the current availability of
novel technologies, platforms and bioinformatic tools.
Today, therapies are being rationally designed to target the
precise genetic alterations with better clinical outcomes
with reduced morbidity. Therefore, molecular profiling of
tumors to identify the multiplicity of alterations in a tumor
is an essential and necessary companion for targeted
therapies.
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Introduction
Molecular profiling (MP) encompasses the testing of
multiple biomarkers to evaluate the underlying genetic
alterations present in a tumor at any one point in time [1–
3]. To date molecular profiles may consist of multiple gene
mutational analyses, gene copy number changes by
fluorescence in situ hybridization (FISH), gene expression
profiles measured by microarrays (MA) and protein
expression by immunohistochemistry (IHC). This approach
is superior to the testing of one biomarker target which
does not take into account the complexity of multiple
signaling pathways and cross talk [4].
The cancer literature is replete with studies exploring
single biomarkers in clinical trials designed to test single
agents or biomarker analyses performed as a post hoc
analysis. Although there are a plethora of biomarkers that
have emerged that may positively prognosticate or predict
response to various therapies, the clinical utility and
adoption of this approach has been slow due to validation
concerns, reproducibility and translation into clinical care
[5–7].
Since comprehensive MP uses a multi-dimensional
approach to testing, it is inherently more complex and
requires extensive validation. There is significant invest-
ment in high cost, high throughput technologies, trained
laboratory work force, and laboratory informatics to
achieve the level of validation required by CLIA or CAP to
offer the test for patient-care. Laboratory developed test-
validations in a CLIA mandated environment typically
requires the following [8]:
a. Specimen type and specimen handling protocols: since
this variable can hugely affect reproducibility of the test,
standardization of specimen handling is imperative.
More and more, the formalin fixed paraffin embedded
tissue is becoming the sample of choice as it is readily
available. This sample type has been shown to perform
adequately for mutational analysis; gene expression
profiles measured by RT-PCR or oligonucleotide arrays,
FISH, and IHC. However, the quality of analysis on this
preferred sample type has to be closely monitored based
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on time to fixation, time in fixative and age of the
samples. Additionally for newer molecular techniques,
internal and external quality checks such as the amount
or percentage of tumor nuclei, the quantity and quality of
DNA and RNA, measurement of internal housekeeping
genes are all important determinants in the overall
quality of results [9–15]. Validation of each component
of the MP assay, whether being performed in a non-profit
hospital-based/academic laboratory or for-profit refer-
ence labs, has to follow the strict CLIA guidelines as
well as guidelines provided by laboratory associations
such as College of American Pathologists (CAP) or
CLS1. For each test offered, per validation guidelines,
the laboratory must document certain performance
characteristics which include:
(a) Accuracy to document that the test produces
expected result by appropriate testing of known
positive and negative samples. From these accu-
racy studies the analytical sensitivity, specificity
and accuracy of the assay can be determined
(b) Precision studies are performed to determine
intra-run and inter-run reproducibility.
(c) The assay will also have to determine appropriate
reference ranges and limit of detection for
appropriate reporting of results. Ongoing quality
assurance and proficiency testing are some other
additional requirements by CLIA
Given the resource investment requirements for con-
ducting these multi-dimensional, labor intense assays, it is
easily conceivable that these assays are increasingly being
offered by large centralized laboratories. (examples include:
Genomic Health Inc., Pathwork Diagnostics and Caris Life
Sciences). The rapidly developing genomic information is
leading to the proliferation of MP services and assays and
their subsequent introduction into clinical care.
One such MP service is the Caris Target Now
TM
. This
service offers a new approach in which an evidence rated
review of the literature based on the the US Preventive
Task Force rating is utilized to identify targets in tumor
tissue associated with current therapies [16]. Using a
technology and platform agnostic approach, various targets
are analyzed using a combination of assays such as gene
sequencing, oligonucleotide microarray, mutational analy-
ses, copy number changes using FISH analysis and protein
expression by IHC.
This particular approach for MP to measure molecular
targets was studied in a feasibility study in 2006 [17] and
most recently in a multi-center clinical trial, across nine
different cancer centers in the US. Using the Caris Life
Sciences Caris Target Now
TM
MP service, Von Hoff et al.
[18] reported a longer PFS for patients on MP-directed
therapy than physician choice for 27 % of patients (95 % CI,
17–38 % P = 0.007). This study used a novel study design
in which the patient served as their own controls and PFS
ratio was determined by actual comparison of PFS on MP
therapy versus PFS on patient’s last prior therapy. For the
participants (18/66) who had a PFS C1.3 overall survival was
9.7 months compared to 5 months on physician directed
therapy. Interestingly, MP of tumors yielded actionable
targets in 98 % by this assay indicating that such an approach
is feasible. However, it is to be noted that the targets iden-
tified may involve off-label use of therapies [18]. Whereas
Von Hoff et al. study was restricted to advanced stage
patients with metastases and refractory tumors, the approach
may have significant benefits when used earlier.
Using the same Caris Target Now
TM
service, Shacham-
Shmuel et al. [19], reported two patients with advanced
stage colon cancers in which identification of a target
MGMT by IHC with this assay, led to measurable response
to temozolomide treatment with decrease in serum markers
and tumor shrinkage on CT. Using the same assay, dis-
covery of targets was also reported in a interdigitating
reticulum cell sarcoma, an exceedingly rare tumor [20].
Tsimberdou et al. [21] presented the MD Anderson expe-
rience using MP. Median time to treatment failure (TTF) in
161 patients with one aberration treated with matched tar-
geted therapy was 5.3 months (95 % CI: 4.1, 6.6) versus
3.2 months (95 % CI: 2.9–4.0) for their prior systemic
antitumor therapy (prior to referral to phase I)
(P = 0.0003). For patients with one aberration, the CR-PR
rate was 29 % with matched targeted therapy versus 8 %
without matching (P = 0.0001). The CR ? PR rate was
6 % in 438 patients without molecular testing treated on the
same studies. Interestingly, these rates compare favorably
with those reported by Von Hoff et al. for the Caris Target
Now service. These preliminary results suggest that in early
clinical trials, matching patients with targeted drugs based
on their molecular profile results in (a) longer TTF com-
pared to their prior therapy and (b) higher rates of response,
survival and TTF compared to those seen in patients treated
without molecular matching. The Battle trial for personal-
izing therapy for lung cancer identified targets of high
interest in treatment of lung cancer and using an adaptive
randomized trial utilized real time biomarker analyses to
predict sensitivity or resistance to targeted agents [22]. A
similar trial I-Spy 2 also employs this groundbreaking
clinical trial model that uses genetic or biological markers
(‘‘biomarkers’’) from individual patient’s tumors to screen
promising new treatments, identifying which treatments are
most effective in specific types of patients [23]. In addition,
this innovative adaptive trial design similar to Battle Trial
will enable researchers to use early data from one set of
patients to guide decisions about which treatments might be
more useful for patients later in the trial, and eliminate
ineffective treatments more quickly.
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With more focus on the MP of tumors and greater
realization of the limitations of one-biomarker—one target
approach, cancer treatment in the US is about to experience
a major revolution. Upfront MP of tumors at the time of
diagnosis and subsequently at all points of tumor recur-
rence, whether local or distant, will change the treatment of
oncology care forever. This will hopefully lead to better
control of cancer, improved outcomes for patients, and a
more rational and less expensive oncology care.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
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